Hypoxia News and Research

RSS
Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.
Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

TLR4 may provide new strategy for treating patients with PDAC: Study

TLR4 may provide new strategy for treating patients with PDAC: Study

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis announces regaining of rights to develop and commercialize XL184

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

Researchers establish link between air pollution and SDB

Researchers establish link between air pollution and SDB

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

High oxygen delivery after postcardiac arrest leads to higher rate of death in hospitals

High oxygen delivery after postcardiac arrest leads to higher rate of death in hospitals

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

New FDA approved Landon Medical LM-800 Finger Pulse Oximeter available for home use

New FDA approved Landon Medical LM-800 Finger Pulse Oximeter available for home use

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Gene therapy shows positive effects in rat models of PAH: Researchers

Gene therapy shows positive effects in rat models of PAH: Researchers

Sleep apnea increases insulin resistance: Study

Sleep apnea increases insulin resistance: Study

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.